Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tulisokibart in Psoriatic Arthritis
NCT07486960Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Apr 2026
- Primary completion
- Feb 2027
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 2 trial of tulisokibart in psoriatic arthritis (PsA), sponsored by Merck & Co.. Started Apr 2026; status: active, not recruiting.
02
Drugs
tulisokibart
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT07486960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07486960.